SCHEMBL23977248

SCHEMBL23977248

CC(C)(C)[S+]([O-])/N=C1\CCCc2cc(F)ccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.36
MAPT P10636 5/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
SRD5A1 P18405 2/20 0.32
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
CYP19A1 P11511 4/20 0.31
CYP11B1 P15538 3/20 0.31
CYP11B2 P19099 3/20 0.31
MAPK1 P28482 1/20 0.31
PTGS2 P35354 1/20 0.30
MAOA P21397 1/20 0.30
MAOB P27338 1/20 0.30
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30062796 1.00 GPR3 (0.36) GPR3MAPTALDH1A1LMNAKMT2A
SCHEMBL24781210 1.00 GPR3 (0.36) GPR3MAPTALDH1A1LMNAKMT2A
SCHEMBL20305455 0.92 GPR3 (0.38) GPR3SRD5A1CYP19A1CYP11B1CYP11B2
SCHEMBL22374934 0.92 GPR3 (0.38) GPR3SRD5A1CYP19A1CYP11B1CYP11B2
SCHEMBL29689960 0.92 GPR3 (0.38) GPR3SRD5A1CYP19A1CYP11B1CYP11B2
SCHEMBL26962621 0.92 GPR3 (0.38) GPR3SRD5A1CYP19A1CYP11B1CYP11B2
SCHEMBL29689999 0.80 GPR3 (0.38) GPR3SRD5A1
SCHEMBL29690456 0.80 GPR3 (0.38) GPR3SRD5A1
SCHEMBL26962454 0.80 GPR3 (0.38) GPR3SRD5A1
SCHEMBL12564940 0.80 GPR3 (0.51) GPR3MAPTALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE NOVARTIS AG (CH) 2022-12-22 US disclosed
WO-2021217508-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE HIF1AN, HIF1A, EGLN2 GPR3 2780/4885MAPT 4395/4885ALDH1A1 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.